Table 2 Percentage of thyroid carcinoma cells determined by FACS analysis in each cell cycle phase following 24 h of treatment with sorafenib or vehicle

BHT101

Papillary

Unstimulated

4.5 ± 0.6

58.3 ± 3.9

17.7 ± 0.9

24.0 ± 1.3

Sorafenib 24 h

60.2 ± 6.4*

72.1 ± 5.8*

13.4 ± 0.7*

14.5 ± 0.9*

B-CPAP

Papillary

Unstimulated

6.8 ± 2.3

57.1 ± 2.7

14.0 ± 1.1

28.9 ± 1.4

Sorafenib 24 h

62.3 ± 7.3*

69.8 ± 4.6*

23.1 ± 1.2*

7.1 ± 0.4*

TPC1

Papillary

Unstimulated

3.1 ± 0.4

48.1 ± 3.5

25.3 ± 1.6

26.6 ± 1.3

Sorafenib 24 h

72.4 ± 5.9*

57.6 ± 4.2*

27.6 ± 3.5

14.8 ± 0.8*

FTC133

Follicular

Unstimulated

1.5 ± 0.3

57.0 ± 3.5

13.7 ± 0.8

29.3 ± 1.5

Sorafenib 24 h

22.1 ± 3.4*

46.9 ± 4.4*

8.7 ± 0.5*

44.4 ± 2.9*

FTC236

Follicular

Unstimulated

1.2 ± 0.2

64.1 ± 5.0

12.1 ± 0.9

23.8 ± 1.1

Sorafenib 24 h

35.2 ± 3.7*

36.0 ± 3.1*

15.6 ± 1.0*

48.4 ± 3.7*

FTC238

Follicular

Unstimulated

0.7 ± 0.1

46.1 ± 2.9

9.3 ± 0.6

44.6 ± 5.8

Sorafenib 24 h

43.0 ± 5.0*

24.2 ± 1.4*

11.0 ± 1.7

64.6 ± 6.6*

ML1

Follicular

Unstimulated

1.0 ± 0.1

56.5 ± 3.2

18.1 ± 1.2

25.4 ± 1.3

Sorafenib 24 h

40.4 ± 3.2*

59.9 ± 2.7

25.5 ± 1.8*

14.4 ± 0.8*

TT2609

Follicular

Unstimulated

1.6 ± 0.2

57.6 ± 4.6

11.5 ± 1.3

30.9 ± 1.8

Sorafenib 24 h

21.5 ± 3.0*

54.7 ± 6.0

13.1 ± 1.6

32.2 ± 3.1

SW1736

Anaplastic

Unstimulated

2.2 ± 0.3

46.0 ± 2.9

10.1 ± 1.1

43.9 ± 2.7

Sorafenib 24 h

53.6 ± 3.9*

68.1 ± 5.5*

9.7 ± 0.7

22.2 ± 1.2*

C643

Anaplastic

Unstimulated

1.0 ± 0.1

50.5 ± 3.7

15.1 ± 0.8

34.4 ± 2.8

Sorafenib 24 h

43.8 ± 4.0*

38.6 ± 2.6*

11.5 ± 0.5*

49.9 ± 3.5*

HTh7

Anaplastic

Unstimulated

5.9 ± 0.8

52.2 ± 3.5

14.5 ± 0.8

33.3 ± 1.8

Sorafenib 24 h

25.7 ± 3.4*

76.9 ± 6.4*

1.2 ± 0.1*

21.9 ± 0.9*

HTh83

Anaplastic

Unstimulated

5.6 ± 0.3

36.5 ± 2.6

24.3 ± 1.7

39.2 ± 2.0

Sorafenib 24 h

74.7 ± 5.7*

35.0 ± 5.2

34.5 ± 1.9*

30.5 ± 1.5*